The six-carbon polyol inositol is a uniquely versatile compound in biology. Myo-inositol is the major naturally occurring isomer of nine possible inositol isomers and is critical for the phosphoinositide (PI) cycle as a substrate for PI synthase ([@b2]). [@b1] reported that epi-inositol is not a substrate for PI synthase, but a number of experiments suggest that epi-inositol might affect the PI cycle. Like myo-inositol, epi-inositol was shown to reverse Li-pilocarpine seizures ([@b12]), strongly suggesting that epi-inositol could enter the PI cycle. Furthermore, accumulation of \[3H\]-cytidine monophosphate phosphatidate (CMP-PA) in Chinese hamster ovary (CHO) cells during Li treatment is reversible with myo-inositol, and [@b10] found that epi-inositol was about 30%--40% as active as myo-inositol in reversing such accumulation. Myo-inositol has been found to have antidepressant and antianxiety effects in animal models ([@b3]) and in controlled studies in patients ([@b8]). Recently, [@b5] studied epi-inositol in the elevated plus maze model of rat anxiety and surprisingly found it much more active than myo-inositol.

In this report, we explored the effects of epi-inositol in the Porsolt Forced Swim Test model of depression (FST) and have attempted to replicate our previous results in the Elevated Plus Maze.

For the FST, rats (n = 10/group) were tested with two exposures to a water tank spaced 24 hours apart. Epi-inositol treatment (5 g/kg diluted in deionized water to 20 mL/kg) consisted of two injections, the first immediately after the first exposure to the water tank and the second 5 hours prior to the second exposure (the test session). This dose and schedule of injections was chosen because it was demonstrated to be effective in this model with myo-inositol ([@b6], [@b4]). The Elevated Plus-Maze model for anxiety study was designed to replicate our previously reported experiment ([@b5]) and included 3 groups (n = 10/group) receiving chronic (11 days) daily intra-peritoneal injections at a dose of 1.2 g/kg myo-inositol, epi-inositol, and control solutions. Five to six hours after the last injection, animals were tested in an elevated plus-maze. A student's t-test was used to analyze the FST results. Since data were not homogenous (Levene test: F(2,26) = 3.8, p \< 0.04), the Plus-Maze measures were analyzed using a Kruskall-Wallis nonparametric analysis of variance (ANOVA) followed by similar post-hoc comparisons of open/closed arms entries and time ratio.

Epi-inositol treatment did not affect immobility (t(18) = 0.4, NS), swimming (t(18) = 0.84, NS), or struggle time (t(18) = 0.24, NS) in the FST. As previously reported, myo-inositol had an anxiolytic-like effect in the plus-maze model as demonstrated by significant increase in open/closed arms entries ratio (Kruskall-Wallis ANOVA, χ^2^(2) = 7.2, p \< 0.03, post hoc tests myo-inositol different than control) and a similar trend for increase in open/closed arms time ratio (χ^2^2(2) = 5.6, p = 0.06). However, in contrast with our previous findings, epi-inositol had no anxiolytic effects in the elevated plus-maze model.

Epi-inositol was not active in the FST, and the previous finding that epi-inositol is more effective than myo-inositol in the elevated plus maze model of anxiety was not replicated. Effects of myo-inositol in the FST have been shown to be mediated by the serotonergic system, specifically via 5-HT2A/C receptors ([@b4]). Epi-inositol is not a substrate for PI synthase, is not incorporated into phosphatidylinositol, and does not enter into the PI cycle second messenger system ([@b1]). The present finding therefore supports the hypothesis that myo-inositol's antidepressant and anxiolytic effectiveness is based on its ability to affect the PI cycle activity.

Epi-inositol, similar to myo-inositol, was active in the reversing of biochemical and behavioral effects of lithium action ([@b7]; [@b9]), and in yeast, epi-inositol was shown to affect the expression of genes involved in the metabolism of myo-inositol ([@b11]). Therefore, the effect of epi-inositol, which is not incorporated into the PI cycle, in biochemical and behavioral models of lithium action could be explained by an epi-inositol effect on myo-inositol metabolism at the level of gene expression. However, as demonstrated by the present results, epi-inositol may not be enough to independently induce behavioral change in standard models of depression or anxiety at the same design where myo-inositol induces a clear and replicable behavioral change.
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